BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...
DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR ...
Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...
Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...
Bristol-Myers Squibb's stock surged to a new 52-week high, trading at $61.90 after closing at $60.18. Analysts have updated ...
Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus ...
ReviveMed's AI platform analyzes metabolite data, revealing insights into diseases and streamlining drug development for ...
Actor Taye Diggs sits down with TODAY’s Jenna Bush Hager and guest co-host Regina Hall to talk about Bristol Myers Squibb, an organization that he is an ambassador for and opens up about how the ...
Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward ...
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced it was named a Customers' Choice in the 2025 Gartner Peer Insights ?Voice of the Customer' for Primary Storage ...
PC era" aren't just buzzwords; they represent today's reality. Within the GIS industry, mobile internet and mobile GIS technology have transformed how we acquire, visualize, analyze, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback